TrialBMC cancer2022

IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.

Taigo Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.